• 대한의생명과학회지
• /
• 제22권4호
• /
• pp.160-166
• /
• 2016

To provide a basis for a homogeneous fluorescence resonance energy transfer (FRET) immunoassay for celiac disease, we carried out a FRET experiment using guinea pig tissue transglutaminase (tTG) and antibodies to tTG (anti-tTG) purified from rat serum. Fluorescein was utilized as the probe, and a nonfluorescent dye, QSY 7 served as the quencher. We labeled anti-tTG and tTG with fluorescein isothiocyanate and QSY 7 succinimidyl ester, respectively. Fluorescein-labeled anti-tTG was the donor, and QSY 7-labeled tTG was the acceptor of the FRET experiment. When we titrated fluorescein-labeled anti-tTG with QSY 7-labeled tTG, we observed a large decrease in the steady-state fluorescence intensity, which was due to strong FRET from fluorescein-labeled anti-tTG to QSY 7-labeled tTG. Using time-resolved fluorescence spectroscopy, we could also observe a decrease in the fluorescence lifetime, which confirms the steady-state data. We expect that these results might be useful in the development of a novel fluorescence immunoassay for an easy screening and follow-up of celiac patients.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제23권4호
• /
• pp.397-404
• /
• 2020

Purpose: Synbiotics can alleviate some intestinal pathologies or prevent trigger mechanisms for some diseases such as celiac disease (CD). If patients with high levels of anti-tissue transglutaminase (anti-tTG) immunoglobulin A (IgA) antibodies have normal duodenal histology, they are followed as potential CD patients. The aim of this study was to investigate the effect of synbiotic use on the blood levels of anti-tTG antibodies in children. Methods: Eighty-two patients with high anti-tTG levels were included in this study. Patients were randomly divided into two groups. The synbiotic group was treated with a daily dose of a synbiotic including multi-strain probiotics for 20 days. The control group was not administered any medication. Anti-tTG values at baseline and repeat measurements and the percentage change in anti-tTG levels between groups were compared. Results: The anti-tTG level at baseline was 36 U/mL (interquartile range [IQR], 26.4-68 U/mL) in the synbiotic group, and it decreased significantly to 13 U/mL (IQR, 6.5-27.5 U/mL) after 20 days (p<0.05). The anti-tTG level at baseline was 46 U/mL (IQR, 31-89 U/mL) in the control group, which also decreased significantly to 23 U/mL (IQR, 7-41 U/mL) after 20 days (p<0.05). Anti-tTG levels exhibited 73% and 56% decreases in the synbiotic and control groups, respectively (p<0.05). Conclusion: It may be speculated that a synbiotic supplementation can contribute to decreasing anti-tTG levels in children with potential CD.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제25권4호
• /
• pp.312-320
• /
• 2022

Purpose: Screening serologic tests are important tools for the diagnosis of celiac disease (CD). Immunoglobulin (Ig)G anti-deamidated gliadin peptide (anti-DGP) is a relatively new autoantibody thought to have good diagnostic accuracy, comparable to that of anti-tissue transglutaminase (anti-tTG) antibody. Methods: Pediatric patients (n=86) with a clinical suspicion of CD were included. Duodenal biopsy, anti-tTG, and IgG anti-DGP antibody tests were performed. The patients were divided into CD and control groups based on the pathological evaluation of duodenal biopsies. The diagnostic accuracy of serological tests was determined. Results: IgA anti-tTG and IgG anti-DGP antibodies were positive in 86.3% and 95.4% of patients, respectively. The sensitivity, specificity, and diagnostic accuracy of the IgA anti-tTG test were 86.3%, 50.0%, and 68.6%, respectively, and those of the IgG anti-DGP test were 95.4%, 85.7%, and 90.7%, respectively. The area under the receiver operating characteristic (ROC) curve was 0.84 (95% confidence interval [CI], 0.74-0.91) for IgA anti-tTG test and 0.93 (95% CI, 0.86-0.97) for IgG anti-DGP test. The comparison of IgA anti-tTG and IgG anti-DGP ROC curves showed a higher sensitivity and specificity of the IgG anti-DGP test. Conclusion: IgG anti-DGP is a reliable serological test for CD diagnosis in children. High tTG and DGP titers in the serum are suggestive of severe duodenal atrophy. The combined use of IgA anti-tTG and IgG anti-DGP tests for the initial screening of CD can improve diagnostic sensitivity.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제22권4호
• /
• pp.350-357
• /
• 2019

Purpose: This study aimed to evaluate a possible association between the anti-tissue transglutaminase antibody (anti-tTG) titer and stage of duodenal mucosal damage and assess a possible cut-off value of anti-tTG at which celiac disease (CD) may be diagnosed in children in conjunction with clinical judgment. Methods: This observational study was conducted at a gastroenterology clinic in a tertiary hospital from April 2012 to May 2013. Seventy children between 6-months and 18-years-old with suspected CD underwent celiac serology and duodenal biopsy. Statistical analyses were done using SPSS 16. Diagnostic test values were determined for comparing the anti-tTG titer with duodenal biopsy. An analysis of variance and Tukey-Kramer tests were performed for comparing the means between groups. A receiver operating characteristics curve was plotted to determine various cut-off values of anti-tTG. Results: The mean antibody titer increased with severity of Marsh staging (p<0.001). An immunoglobulin (Ig) A-tTG value at 115 AU/mL had 76% sensitivity and 100% specificity with a 100% positive predictive value (PPV) and 17% negative predictive value (NPV) for diagnosis of CD (p<0.001, 95% confidence interval [CI], 0.75-1). Conclusion: There is an association between the anti-tTG titer and stage of duodenal mucosal injury in children with CD. An anti-tTG value of 115 AU/mL (6.4 times the upper normal limit) had 76% sensitivity, 100% specificity, with a 100% PPV, and 17% NPV for diagnosing CD (95% CI, 0.75-1). This cut-off may be used in combination with clinical judgment to diagnose CD.

• Clinical and Experimental Pediatrics
• /
• 제48권6호
• /
• pp.624-633
• /
• 2005

목 적 : 본 연구는 한국인 제 1형 당뇨병 환자들에서 HLADR과 DQ 유전자형 및 갑상선 자가항체(항 TPO 자가항체와 항 thyroglobulin 자가항체)를 분석함으로써, 한국인 제 1형 당뇨병과 관련 있는 특정 HLA 유전자형을 알아보고자 하였고, 이들 제 1형 당뇨병 환자들에서의 갑상선 자가항체의 유병률, 갑상선 질환으로의 발현 및 이들 자가면역성 갑상선염과 HLA 유전자형과의 관련성을 알아보고자 하였다. 방 법 : 총 59명[남아 26명, 검사시 연령 13.7세(5.7-29.9세), 당뇨병 유병기간 7.6년(-1.7-22.5년)]의 제 1형 당뇨병 환자를 대상으로 하였고, 갑상선 질환의 병력 및 가족력이 없는 건강한 200명의 한국인의 HLA 유전자형을 대조군으로 하였다. 59명의 환자 중 갑상선 자가항체 양성인 17명은 중앙기간 3.96년(1일-10.7년) 동안 진찰 및 anti-TPO, anti-TG, $T_3$, $T_4$ 또는 free $T_4$, TSH 검사를 시행하면서 추적 관찰하였다. HLA-DR과 DQ의 유전자 분석은 PCR-SSO, PCR-SSCP, PCR-RFLP 및 PCR-SSP 방법을 이용하였다. 결 과 : 제 1형 당뇨병 환자들에서 대조군에서보다 HLADRB1*0301, *090102, DQB1*0201, *030302, DRB1*0301/*090102, DRB1*090102/*090102, DQB1*0201/*030302, *030302/*030302, *0201/*0302의 빈도가 높았다(Pc<0.05). 15명(25.4%)에서 TPO에 대한 자가항체 양성이었고, 12명(20.3%)에서 TG 자가항체 양성이었으며, 17명(28.8%)은 두 가지 항체 중 한 가지 이상의 항체를 갖고 있었다. 10명(16.9%)은 두 종류의 항체를 모두 갖고 있었다. 갑상선 항체 양성을 보인 이후부터의 추적기간 동안 갑상선기능저하증을 보인 경우는 없었다. 3명(5.1%)의 여아에서 당뇨병 진단 전 또는 후에 갑상선기능항진증이 진단(8.5세, 11세, 13.2세)되었다. 갑상선 자가항체의 유무 및 각각의 항체 종류에 따른 대상군간의 제 1형 당뇨병 진단연령, 갑상선 검사시 연령, 당뇨병 유병기간 및 성별의 차이는 보이지 않았다(P>0.05). 결 론 : 한국인에서는 HLA-DRB1*0301, *090102, DQB1*0201, *030302, DRB1*0301/*090102, *090102/*090102, DQB1*0201/*030302, *030302/*030302, *0201/*0302 등이 제 1형 당뇨병에 대한 감수성 인자였고, 코카시안과는 다른 HLA-DR 및 DQ의 분포가 한국인에서 제 1형 당뇨병의 발생률이 낮은 이유중의 하나를 차지하리라고 생각되었다. 한편, 제 1형 당뇨병 환자들에서 갑상선 자가항체 양성률은 28.8%였고, 이는 한국인 제 1형 당뇨병 환자에서도 갑상선 자가항체 검사가 규칙적으로 시행되어야 함을 시사한다고 하겠다. 한국인 제 1형 당뇨병 환자에서 자가면역성 갑상선 질환에 대한 선별검사 시작 시기와 횟수 등에 대해서는 이들 환자들의 장기적인 추적관찰을 통해 추후 좀더 연구가 필요하리라 생각된다.

• 핵의학기술
• /
• 제13권3호
• /
• pp.152-155
• /
• 2009

목적: 혈중 thyroglobulin 농도 측정(혈중 TG)은 갑상선암 수술 후 재발 및 전이여부를 판단하는데 중요한 지표이다. 최근엔 혈중 TG와 함께 침생검 검체의 washout solution을 이용한 TG 농도 측정(washout TG)이 추적 검사에 빈번히 사용되고 있다. 본 연구는 혈중 TG와 washout TG간에 어떠한 연관성이 있는지 알아보고자 한다. 대상 및 방법: 2007년 1월부터 2008년 2월까지 국립암센터에 내원한 갑상선암 환자 중 washout TG 와 혈중 TG를 함께 측정한 47명 중 혈중 Anti-Tg Ab 양성(${\geq}$100 U/mL)인 환자 6명을 제외한 41명을 대상으로 하였다. 혈중 TG와 washout TG와 세포검사결과와의 연관성도 조사하였다. 결과 및 결론: Washout TG는 혈중 TG보다 현저하게 높았으며 두 경우의 검사결과 간에 유의한 차이를 보였다(p=0.0394). washout TG와 세포검사결과와의 일치도는 87.8%, 혈중 TG와의 일치도는 56.1%였다. washout TG가 양성인 경우는 28명(세포검사결과 양성: 24, 양성의심: 4), 음성인 경우는 13명(세포검사결과 양성의심: 1, 음성: 12)이었다. serum TG가 양성인 경우는 26명(세포검사결과 양성: 17, 양성의심: 3, 음성: 6), 음성인 경우는 15명(세포검사결과 양성: 8, 양성의심: 1, 음성: 6)이었다. 갑상선암에서의 추적 검사로써 washout TG와 혈중 TG가 상호보완적으로 시행되어질 때 재발과 전이를 찾아내는데 유용하다.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• 제24권2호
• /
• pp.197-206
• /
• 2021

Purpose: Celiac disease (CD) is a common autoimmune disease with extra-intestinal manifestations, including neurological disorders. There are few reports to assess various factors in increasing the chances of developing neurological disorders in CD, so we designed this study. Methods: All patients with CD at any age who had been referred to the Celiac Clinic were evaluated for neurological problems. CD was defined as IgA anti-transglutaminase antibodies (anti-tTG) of 18 IU/mL or higher in serology and Marsh type I or more severe in histopathological evaluation. Logistic regression analysis was used to evaluate the impact of various independent variables on the neurological manifestations. Results: A total of 540 patients enrolled in this study. A 360 (66.7%) of patients were children. A 64.8% and 35.2% were female and male, respectively. Overall, 34.1% of patients had neurological manifestation, including headache, neuropathy, epilepsy, and ataxia. The odds of developing neurological manifestations in children were significantly lower than in adults (odds ratio [OR], 0.66; 95% confidence interval [CI], 0.45-0.96; p=0.03) and in patients with gastrointestinal (GI) symptoms significantly higher than in the group without GI manifestations (OR, 1.77; 95% CI, 1.18-2.63; p=0.005). Other variables, including Marsh classification (OR, 0.44; 95% CI, 0.18-1.11; p=0.08) and anti-tTG levels (OR, 1.00; 95% CI, 0.999-1.001; p=0.59) did not significantly increase the chances of developing neurological disorders. Conclusion: Our study showed that increasing age and the presence of GI symptoms, but not serological and histological findings, could increase the chances of developing neurological diseases in CD patients.

• Parasites, Hosts and Diseases
• /
• 제55권5호
• /
• pp.491-503
• /
• 2017

The effects of tyrosine kinase inhibitors (TKIs) were evaluated on growth inhibition of intracellular Toxoplasma gondii in host ARPE-19 cells. The number of tachyzoites per parasitophorous vacuolar membrane (PVM) was counted after treatment with TKIs. T. gondii protein expression was assessed by western blot. Immunofluorescence assay was performed using Programmed Cell Death 4 (PDCD4) and T. gondii GRA3 antibodies. The TKIs were divided into 3 groups; non-epidermal growth factor receptor (non-EGFR), anti-human EGFR 2 (anti-HER2), and anti-HER2/4 TKIs, respectively. Group I TKIs (nintedanib, AZD9291, and sunitinib) were unable to inhibit proliferation without destroying host cells. Group II TKIs (lapatinib, gefitinib, erlotinib, and AG1478) inhibited proliferation up to 98% equivalent to control pyrimethamine ($5{\mu}M$) at $20{\mu}M$ and higher, without affecting host cells. Group III TKIs (neratinib, dacomitinib, afatinib, and pelitinib) inhibited proliferation up to 98% equivalent to pyrimethamine at $1-5{\mu}M$, but host cells were destroyed at $10-20{\mu}M$. In Group I, TgHSP90 and SAG1 inhibitions were weak, and GRA3 expression was moderately inhibited. In Group II, TgHSP90 and SAG1 expressions seemed to be slightly enhanced, while GRA3 showed none to mild inhibition; however, AG1478 inhibited all proteins moderately. Protein expression was blocked in Group III, comparable to pyrimethamine. PDCD4 and GRA3 were well localized inside the nuclei in Group I, mildly disrupted in Group II, and were completely disrupted in Group III. This study suggests the possibility of a vital T. gondii TK having potential HER2/4 properties, thus anti-HER2/4 TKIs may inhibit intracellular parasite proliferation with minimal adverse effects on host cells.